In human breast cancer, the CD44+/ESA+/CD24−/low cells have been tested as BCSCs, since they are able to differentiate into cells with diverse phenotypes, and have tumorous pluripotency to generate mammary tumors and metastases in vivo [2,5,13]. The gene discussed is CD44; the disease is breast cancer.